NO323623B1 - Isolert og renset TNF-<alfa>-omdannende enzym (TACE)-polypeptid med evnen til a omdanne TNF-<alfa> fra formen pa 26 kD til formen pa 17 kD, isolerte og rensede antistoffer, fremgangsmate for pavisning av den TACE-inhiberende aktivitet til et molekyl, isolert nukleinsyre, ekspresjonsvektor, vertcelle, fremgangsmate for fremstilling av et TNF-<alfa>-omdannende enzym (TACE)- polypeptid, anvendelse av TNF-<alfa>-omdannende enzym (TACE)- polypeptid for fremstilling av et medikament for behandling av tumorer, inflammasjon eller fertilitetsforstyrrelser. - Google Patents

Isolert og renset TNF-<alfa>-omdannende enzym (TACE)-polypeptid med evnen til a omdanne TNF-<alfa> fra formen pa 26 kD til formen pa 17 kD, isolerte og rensede antistoffer, fremgangsmate for pavisning av den TACE-inhiberende aktivitet til et molekyl, isolert nukleinsyre, ekspresjonsvektor, vertcelle, fremgangsmate for fremstilling av et TNF-<alfa>-omdannende enzym (TACE)- polypeptid, anvendelse av TNF-<alfa>-omdannende enzym (TACE)- polypeptid for fremstilling av et medikament for behandling av tumorer, inflammasjon eller fertilitetsforstyrrelser. Download PDF

Info

Publication number
NO323623B1
NO323623B1 NO19975438A NO975438A NO323623B1 NO 323623 B1 NO323623 B1 NO 323623B1 NO 19975438 A NO19975438 A NO 19975438A NO 975438 A NO975438 A NO 975438A NO 323623 B1 NO323623 B1 NO 323623B1
Authority
NO
Norway
Prior art keywords
tace
tnf
polypeptide
isolated
converting enzyme
Prior art date
Application number
NO19975438A
Other languages
English (en)
Norwegian (no)
Other versions
NO975438D0 (no
NO975438L (no
Inventor
Roy A Black
Douglas Pat Cerretti
Charles Rauch
Carl J March
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/655,345 external-priority patent/US5830742A/en
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of NO975438D0 publication Critical patent/NO975438D0/no
Publication of NO975438L publication Critical patent/NO975438L/no
Publication of NO323623B1 publication Critical patent/NO323623B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
NO19975438A 1995-06-08 1997-11-26 Isolert og renset TNF-<alfa>-omdannende enzym (TACE)-polypeptid med evnen til a omdanne TNF-<alfa> fra formen pa 26 kD til formen pa 17 kD, isolerte og rensede antistoffer, fremgangsmate for pavisning av den TACE-inhiberende aktivitet til et molekyl, isolert nukleinsyre, ekspresjonsvektor, vertcelle, fremgangsmate for fremstilling av et TNF-<alfa>-omdannende enzym (TACE)- polypeptid, anvendelse av TNF-<alfa>-omdannende enzym (TACE)- polypeptid for fremstilling av et medikament for behandling av tumorer, inflammasjon eller fertilitetsforstyrrelser. NO323623B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48245895A 1995-06-08 1995-06-08
US50461495A 1995-07-20 1995-07-20
US08/655,345 US5830742A (en) 1995-06-08 1996-05-23 TNF-α converting enzyme
PCT/US1996/008407 WO1996041624A1 (en) 1995-06-08 1996-06-03 TNF-α CONVERTING ENZYME

Publications (3)

Publication Number Publication Date
NO975438D0 NO975438D0 (no) 1997-11-26
NO975438L NO975438L (no) 1998-02-06
NO323623B1 true NO323623B1 (no) 2007-06-18

Family

ID=27413615

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19975438A NO323623B1 (no) 1995-06-08 1997-11-26 Isolert og renset TNF-<alfa>-omdannende enzym (TACE)-polypeptid med evnen til a omdanne TNF-<alfa> fra formen pa 26 kD til formen pa 17 kD, isolerte og rensede antistoffer, fremgangsmate for pavisning av den TACE-inhiberende aktivitet til et molekyl, isolert nukleinsyre, ekspresjonsvektor, vertcelle, fremgangsmate for fremstilling av et TNF-<alfa>-omdannende enzym (TACE)- polypeptid, anvendelse av TNF-<alfa>-omdannende enzym (TACE)- polypeptid for fremstilling av et medikament for behandling av tumorer, inflammasjon eller fertilitetsforstyrrelser.

Country Status (13)

Country Link
EP (1) EP0830130B9 (de)
JP (1) JP4326022B2 (de)
AT (1) ATE274346T1 (de)
AU (1) AU712759C (de)
CA (1) CA2222650C (de)
DE (1) DE69633231T2 (de)
DK (1) DK0830130T3 (de)
ES (1) ES2227598T3 (de)
IL (1) IL122305A0 (de)
NO (1) NO323623B1 (de)
NZ (2) NZ312285A (de)
PT (1) PT830130E (de)
WO (1) WO1996041624A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180403B1 (en) 1999-10-28 2001-01-30 Isis Pharmaceuticals Inc. Antisense inhibition of tumor necrosis factor alpha converting enzyme (TACE) expression
US6255064B1 (en) 1996-03-01 2001-07-03 The Procter & Gamble Company Disintegrin metalloprotease and its use
JP2000507943A (ja) * 1996-03-26 2000-06-27 グラクソ、グループ、リミテッド 腫瘍壊死因子αコンバーターゼ
WO1998002557A2 (en) * 1996-07-12 1998-01-22 Schering Corporation MAMMALIAN TNF-α CONVERTASES
US5853977A (en) * 1996-07-12 1998-12-29 Schering Corporation Mammalian TNF-α convertases
US6046031A (en) * 1997-01-21 2000-04-04 Human Genome Sciences, Inc. Metalloproteinases
WO1998037092A2 (en) * 1997-02-25 1998-08-27 The Procter & Gamble Company Use of a novel disintegrin metalloprotease
US6551857B2 (en) 1997-04-04 2003-04-22 Elm Technology Corporation Three dimensional structure integrated circuits
US6548633B1 (en) 1998-12-22 2003-04-15 Genset, S.A. Complementary DNA's encoding proteins with signal peptides
CA2319040A1 (en) * 1998-02-04 1999-08-12 Immunex Corporation Crystalline tnf-.alpha.-converting enzyme and uses thereof
US6842704B2 (en) 1998-02-04 2005-01-11 Immunex Corporation Crystalline TNF-α-converting enzyme and uses thereof
US6632667B1 (en) 1999-10-28 2003-10-14 Isis Pharmaceuticals, Inc. Modulation of L-selectin shedding via inhibition of tumor necrosis factor-α converting enzyme (TACE)
EP1449538A1 (de) * 2003-02-21 2004-08-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Modulation der EGF Rezeptor Signalübertragung durch Hemmung von TACE oder Amphiregulin
WO2005030798A2 (en) 2003-09-24 2005-04-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services TNFαCONVERTING ENZYME INHIBITORY AGENTS AND STIMULATORY AGENTS-
WO2008025747A1 (en) * 2006-08-28 2008-03-06 Ares Trading S.A. Process for the purification of fc-fusion proteins
SI2061803T2 (sl) * 2006-08-28 2023-01-31 Ares Trading S.A. Postopek za čiščenje proteinov, ki vsebujejo FC
EP2670775A1 (de) 2011-02-01 2013-12-11 Cancer Research Technology Limited Anti-tace-antikörpermoleküle und verwendungen davon

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05501351A (ja) * 1989-08-16 1993-03-18 カイロン　コーポレイション プロホルモンタンパク質に対する開裂部位阻止抗体及びその使用
AU5940090A (en) * 1989-08-16 1991-04-03 Cetus Oncology Corporation Compositions for the inhibition of protein hormone formation and uses thereof
WO1994000555A2 (en) * 1992-06-25 1994-01-06 Cetus Oncology Corporation Compositions for the inhibition of protein hormone formation and uses thereof
WO1992000378A1 (de) * 1990-06-22 1992-01-09 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Dna-sequenz für eine serin-protease und damit zusammenhängende gegenstände
WO1992002822A1 (en) * 1990-08-06 1992-02-20 Cetus Corporation Methods for the identification of cytokine convertase inhibitors
WO1995024501A1 (en) * 1994-03-07 1995-09-14 Cetus Oncology Corporation Compositions for the inhibition of tnf formation and uses thereof
JP2000507943A (ja) * 1996-03-26 2000-06-27 グラクソ、グループ、リミテッド 腫瘍壊死因子αコンバーターゼ

Also Published As

Publication number Publication date
AU712759C (en) 2001-08-09
NO975438D0 (no) 1997-11-26
AU6378196A (en) 1997-01-09
ATE274346T1 (de) 2004-09-15
AU712759B2 (en) 1999-11-18
DE69633231D1 (de) 2004-09-30
CA2222650C (en) 2009-10-13
ES2227598T3 (es) 2005-04-01
MX9709744A (es) 1998-07-31
EP0830130B1 (de) 2004-08-25
DE69633231T2 (de) 2005-08-04
EP0830130B9 (de) 2004-12-29
CA2222650A1 (en) 1996-12-27
NO975438L (no) 1998-02-06
JP2002515020A (ja) 2002-05-21
EP0830130A1 (de) 1998-03-25
EP0830130A4 (de) 2000-03-29
IL122305A0 (en) 1998-04-05
JP4326022B2 (ja) 2009-09-02
DK0830130T3 (da) 2004-12-20
WO1996041624A1 (en) 1996-12-27
NZ312285A (en) 2001-04-27
NZ510390A (en) 2002-11-26
PT830130E (pt) 2004-11-30

Similar Documents

Publication Publication Date Title
US7695948B2 (en) Antibodies that bind TNF-α converting enzyme
US5830742A (en) TNF-α converting enzyme
NO323623B1 (no) Isolert og renset TNF-&lt;alfa&gt;-omdannende enzym (TACE)-polypeptid med evnen til a omdanne TNF-&lt;alfa&gt; fra formen pa 26 kD til formen pa 17 kD, isolerte og rensede antistoffer, fremgangsmate for pavisning av den TACE-inhiberende aktivitet til et molekyl, isolert nukleinsyre, ekspresjonsvektor, vertcelle, fremgangsmate for fremstilling av et TNF-&lt;alfa&gt;-omdannende enzym (TACE)- polypeptid, anvendelse av TNF-&lt;alfa&gt;-omdannende enzym (TACE)- polypeptid for fremstilling av et medikament for behandling av tumorer, inflammasjon eller fertilitetsforstyrrelser.
CA2296766C (en) Aggrecan degrading metallo proteases
JP2000506005A (ja) ２ｆ１と呼ばれる受容体タンパク質
EP1045905A2 (de) Il-17rh dna und polypeptides
JP2002500011A (ja) Ｖ２０１ｄｎａ及びポリペプチド
US20090017492A1 (en) SVPH1-26 DNA and polypeptides
AU752369B2 (en) TNF-alpha converting enzyme
JP2002508969A (ja) 精巣特異的ヒトｓｖｐｈ１−８プロテイナーゼ
JP2001526915A (ja) Ｖ１９６ｄｎａ及びポリペプチド
MXPA97009744A (en) Enzima convertidora tnf-a
WO1999033984A1 (en) V197 dna and polypeptides

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees